Full-Time

Key Account Manager

Confirmed live in the last 24 hours

argenx

argenx

1,001-5,000 employees

Biotechnology for autoimmune diseases and cancer

No salary listed

Senior, Expert

Alberta, Canada + 2 more

More locations: British Columbia, Canada | Saskatchewan, Canada

Field based with attendance at head office when required, generally 1-2 days per quarter. Travel 25-50% and coverage of large geographies including multiple provinces.

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • Highly developed selling skills, commercial acumen and business insights
  • Exceptional communication skills, with a demonstrated ability to adapt to different customer types and circumstances
  • High level of influencing and negotiation skills
  • Consistent successful sales track record (including specialty/hospital experience)
  • Significant key account management experience and capabilities
  • Previous evidence of successful working in a cross-functional team
  • Ability to translate business insights into commercial action plan
  • Ability to demonstrate strong commercial focus and business acumen
  • Ability to understand and communicate high level scientific data
  • Sound understanding of the IMC code and implications for field representatives
Responsibilities
  • Achieve or exceed sales or targeted goals
  • Work collaboratively with the account team to drive actions that secure and maintain appropriate access for VYVGART
  • Deliver all field-based sales metrics and activities within the Plan of Action, including (but not limited to): Agreed key performance indicators (e.g.: sales, market share, growth, etc.), Activity/coverage (of target customers), Selling skills, Account plans/account management skills/business plans, Account formulary, guideline and treatment algorithm goals
  • Submit accurate and timely expense reports, maintain account records and submit timely and thorough account and territory reports
  • To lead by example and conduct all activities within the letter and spirit of the Innovative Medicines Canada code of ethical practices, in addition to all company policies and procedures
  • Support the development of Key Opinion Leaders from target accounts
  • Develop strong relationships by understanding each customer’s needs, goals and competitive product standing
  • Lead the production, documentation and implementation of detailed account level business plans, aligned with regional and national brand objectives
  • Drive account focused activity that is led by local needs and priorities and aligns with the brand strategy for VYVGART
  • Foster true cross-functional collaboration focused on delivering commercial success
  • Provide key account-level insights into brand planning to ensure that the VYVGART strategy and tactics are fit for purpose
  • Develop expertise in neurology/rare disease as well as detailed account level knowledge
  • Coordinate all argenx Canada account level interactions
  • Maintain a high degree of competence in the areas of product knowledge, disease state knowledge, and industry knowledge impacted by argenx products
  • Development of a comprehensive, territory specific business plan which includes strategies and tactics aimed at achieving annual sales goals set by management to rigorously review and ensure all account level activities align with the brand strategy, reviewing documentation in accordance with the relevant governance processes
  • To lead the account team to deliver focused account plans to support and achieve sales targets within the given timeframe
  • To ensure that all knowledge management and CRM systems are maintained in accordance with argenx standards and operating procedures
  • Ensure expenditure is within agreed budget
Desired Qualifications
  • Proven working knowledge, experience and customer relationships within territory
  • Prior market access experience – field or head-office based
  • Experience working in neurology or rare diseases

argenx develops treatments for severe autoimmune diseases and cancer through biotechnology. The company focuses on creating therapeutic antibodies, which are proteins designed to target specific diseases. One of their main products, cusatuzumab, is being developed with Janssen R&D to treat blood cancers like leukemia. What sets argenx apart from its competitors is its strong emphasis on collaboration with academic institutions and industry partners to turn scientific research into effective therapies. The company's goal is to advance immunology solutions that can significantly improve patient outcomes in challenging medical conditions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • argenx's cusatuzumab benefits from personalized medicine trends in oncology.
  • Steroid-sparing therapeutics collaboration aligns with demand for reduced side effects.
  • Advancing multiple Phase 2 trials by 2024 accelerates candidate identification.

What critics are saying

  • Increased competition in immunology may impact argenx's market share.
  • Failure of efgartigimod in pemphigus could reduce investor confidence.
  • Regulatory scrutiny on drug pricing may affect argenx's revenue streams.

What makes argenx unique

  • argenx collaborates with Janssen R&D on cusatuzumab for leukemia treatment.
  • Focus on autoimmune diseases with innovative FcRn blockers differentiates argenx.
  • Partnerships with academic institutions enhance argenx's research capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

1%
Stock Titan
Feb 25th, 2025
argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference.

Business Wire
Nov 22nd, 2024
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML

Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML

Clinical Trial Vanguard
Nov 20th, 2024
Steritas & Argenx Announce Collaboration to Advance Steroid-Sparing Therapeutics

Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company Argenx.

BioSpace
May 9th, 2024
Argenx Reports First Quarter 2024 Financial Results And Provides Business Update

$398 million in first quarter global net product sales. FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024. On track to submit filing for pre-filled syringe (PFS) in second quarter 2024

BioSpace
May 2nd, 2024
Argenx To Report First Quarter 2024 Financial Results And Business Update On May 9, 2024

Amsterdam, the Netherlands – argenx (Euronext Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update.A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.Dial-in numbers:Belgium 32 800 50 201. France 33 800 943355. Netherlands 31 20 795 1090